M&A Deal Summary |
|
|---|---|
| Date | 2020-01-07 |
| Target | PharmAkea |
| Sector | Life Science |
| Buyer(s) | Galecto |
| Sellers(s) |
Bay City Capital
Celgene |
| Deal Type | Merger |
SEARCH BY
Galecto is a clinical-stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets that are at the heart of fibrosis, inflammation, and cancer. Galecto was formed in 2011 and is based in Copenhagen, Denmark.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Merger M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 2 |
| Year: 2020 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2025-11-10 |
Damora
Waltham, Massachusetts, United States Damora is a biotechnology company focused on developing therapeutic antibodies targeted at mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET) and myelofibrosis (MF). Damora is based in Waltham, Massachusetts. |
Buy | $285M |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1997 |
| PE ASSETS | 1.3B USD |
| Size | Large |
| Type | Sector Focused |
Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 59 of 63 |
| Sector: Life Science M&A | 42 of 46 |
| Type: Merger M&A Deals | 2 of 4 |
| State: California M&A | 31 of 33 |
| Country: United States M&A | 56 of 60 |
| Year: 2020 M&A | 1 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-11-22 |
Interleukin Genetics
Waltham, Massachusetts, United States Interleukin Genetics, Inc. is a genetics-based personalized health company that develops genetic tests for use in the emerging personalized health market. Our vision is to build a leading personalized health and wellness company. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-05-27 |
Conatus Pharmaceuticals
San Diego, California, United States Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. Conatus Pharmaceuticals was founded in 2005 and is based in San Diego, California. |
Sell | - |
| Category | Company |
|---|---|
| Founded | 1980 |
| Sector | Life Science |
| Employees | 6,971 |
| Revenue | 13.0B USD (2017) |
Celgene Corp. is an integrated biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. Celgene Corp. was established in 1980 and is headquartered in Summit, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 3 of 3 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Merger M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 2 of 2 |
| Year: 2020 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-08-26 |
Otezla
United States Otezla is a treatment in the post-topical, pre-biologic segment in its approved indications. Otezla is currently approved for three indications in the U.S.—the treatment of patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy; adult patients with active psoriatic arthritis; and adult patients with oral ulcers associated with Behçet's Disease. |
Sell | $13.4B |
